115103-85-0
基本信息
化合物PROPANOIC ACID
(E)-3-[[[3-[2-(7-氯-2-喹啉基)乙烯基]苯基][[3-(二甲基氨基)-3-氧代丙基]硫基]甲基]硫基]丙酸钠盐
L-660
MK-571 Sodium
Verlukast sodium
MK-571 sodium saL
MK-571 SODIUM HYDRATE
MK-571 sodium salt hydrate
L-660
711
MK571
MK 571
L660711
L-660711
5-(3-(2-(7-Chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acid sodium salt hydrate
(E)-3-[[[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid sodium salt
物理化学性质
| 储存条件 | Keep in dark place,Sealed in dry,Store in freezer, under -20°C |
| 溶解度 | H2O：可溶15mg/mL，澄清 |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 26-36/37 |
| WGK Germany | 3 |
常见问题列表
|
LTD 4 0.22 nM (Ki, In guinea pig lung) |
LTD 4 2.1 nM (Ki, In human lung) |
MK-571 (L660,711) is a potent and selective competitive inhibitor of [ 3 H]leukotriene D4 binding in guinea pig (K i value, 0.22 nM) and human (K i value, 2.1 nM) lung membranes. MK-571 is essentially inactive versus [ 3 H]LTC4 binding with IC 50 values of 23±11 μM (n=16) and 32 μM (n=1) in guinea pig and human lung, respectively. MK-571 competitively antagonizes contractions of guinea pig trachea and ileum induced by leukotriene (LT) D 4 (respective pA 2 values, 9.4 and 10.5) and LTE4 (respective pA 2 values, 9.1 and 10.4) and contractions of human trachea induced by LTD 4 (pA 2 value, 8.5). MK-571 (58 nM) antagonizes contractions of guinea pig trachea induced by LTC 4 in the absence (dose ratio=28) but not in the presence of 45 mM L-serine borate (dose ratio less than 2). MK-571 (19μM) does not block contractions of guinea pig trachea induced by histamine, acetylcholine, 5-hydroxytryptamine, PGF 2 alpha, U-44069, or PGD 2 . In the presence of atropine, mepyramine, and indomethacin, MK-571 (19 μM) inhibits a small component of the response to antigen on guinea pig trachea but completely blocked anti-IgE-induced contractions of human trachea.
MK-571 (L-660,711; i.v.) antagonizes bronchoconstriction induced in anesthetized guinea pigs by i.v. LTC 4 , LTD 4 , and LTE 4 but does not block bronchoconstriction to arachidonic acid, U-44069, 5-hydroxytryptamine, histamine, or acetylcholine. Intraduodenal MK-571 antagonizes LTD 4 (0.2-12.8 μg/kg)-induced bronchoconstriction in guinea pigs, and p.o. MK-571 blockes LTD 4 - and Ascaris-induced bronchoconstriction in conscious squirrel monkeys and ovalbumin-induced bronchoconstriction in conscious sensitized rats treated with methysergide (3 μg/kg). Hypoxia-exposed WT mice are treated with either saline or MK-571 (5 mg/kg/d or 25 mg/kg/d) for 2 more weeks while being maintain in hypoxic conditions. Saline-treated mice display all the hallmarks of PH (i.e., an increase in RVSP, Fulton index, and arterial wall thickness). However, following hypoxia, MK-571-treated mice display lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.